Literature DB >> 16952282

Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

George E Reese1, Vasilis A Constantinides, Constantinos Simillis, Ara W Darzi, Timothy R Orchard, Victor W Fazio, Paris P Tekkis.   

Abstract

AIMS: The aim of this study was to assess the diagnostic precision of antiSaccharomyces cerevisiae (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) in inflammatory bowel disease (IBD) and evaluate their discriminative ability between ulcerative colitis (UC) and Crohn's disease (CD).
METHODS: Meta-analysis of studies reporting on ASCA and pANCA in IBD was performed. Sensitivity, specificity, and likelihood ratios (LR+, LR-) were calculated for different test combinations for CD, UC, and for IBD compared with controls. Meta-regression was used to analyze the effect of age, DNAse, colonic CD, and assay type.
RESULTS: Sixty studies comprising 3,841 UC and 4,019 CD patients were included. The ASCA+ with pANCA- test offered the best sensitivity for CD (54.6%) with 92.8% specificity and an area under the ROC (receiver operating characteristic) curve (AUC) of 0.85 (LR+ = 6.5, LR- = 0.5). Sensitivity and specificity of pANCA+ tests for UC were 55.3% and 88.5%, respectively (AUC of 0.82; LR+ = 4.5, LR- = 0.5). Sensitivity and specificity were improved to 70.3% and 93.4% in a pediatric subgroup when combined with an ASCA- test. Meta-regression analysis showed decreased diagnostic precision of ASCA for isolated colonic CD (RDOR = 0.3).
CONCLUSIONS: ASCA and pANCA testing are specific but not sensitive for CD and UC. It may be particularly useful for differentiating between CD and UC in the pediatric population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952282     DOI: 10.1111/j.1572-0241.2006.00840.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  73 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 2.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 3.  The status of diagnostic markers for inflammatory bowel disease.

Authors:  Poonam Beniwal; Laura Harrell
Journal:  Curr Gastroenterol Rep       Date:  2010-12

Review 4.  Advances in epidemiology and diagnosis of inflammatory bowel diseases.

Authors:  Sobia Ali; Cyrus P Tamboli
Journal:  Curr Gastroenterol Rep       Date:  2008-12

Review 5.  Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management.

Authors:  Giulia D'Arcangelo; Marina Aloi
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

6.  Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease.

Authors:  Moriaki Hatsugai; Manae S Kurokawa; Takefumi Kouro; Kohei Nagai; Mitsumi Arito; Kayo Masuko; Naoya Suematsu; Kazuki Okamoto; Fumio Itoh; Tomohiro Kato
Journal:  J Gastroenterol       Date:  2010-01-05       Impact factor: 7.527

7.  Crohn's colitis complicated by cytomegalovirus infection.

Authors:  Barrett G Levesque; Reetesh Pai; Christine A Cartwright
Journal:  Dig Dis Sci       Date:  2009-07-03       Impact factor: 3.199

8.  Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

Authors:  Brindusa Truta; Dan X Li; Uma Mahadevan; Elena R Fisher; Yunn-Y Chen; Kim Grace; Fernando Velayos; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2013-10-04       Impact factor: 3.199

9.  Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis.

Authors:  Vishal Anand; Anthony S Russell; Ross Tsuyuki; Richard Fedorak
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

Review 10.  Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.

Authors:  Marla Dubinsky; Jonathan Braun
Journal:  Gastroenterology       Date:  2015-08-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.